Answers are grounded in this paper and cite their sources.
Management of refractory and resistant (R/R) Herpes Simplex Virus (HSV-1) infections in hematopoietic stem cell transplant (HSCT) recipients remains challenging. Literature on pritelivir’s efficacy in pediatric patients is scarce. We successfully treated a 7-year-old HSCT recipient with pritelivir for an (R/R) HSV-1 infection and performed therapeutic drug monitoring.
No takes yet. Share an insight, caveat, or question.
Berlandier et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: